Log-in
Sign-up
Webcast
Clinical Trials
Library
Webcast
Clinical Trials
Library
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
COMPLETED
NCT00221754
Pravastatin and Protease Inhibitors in HIV-infected Patients
21
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE2)
HIV Infection
Hypercholesterolemia
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490
Enrollment(s)
156
Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
ACTIVE_NOT_RECRUITING
NCT04618913
Anticoagulation in Patients With Venous Thromboembolism and Cancer
1
Enrollment(s)
1
Study location(s)
OBSERVATIONAL (None)
Neoplasms
Embolism
RECRUITING
NCT06551220
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
800
Enrollment(s)
26
Study location(s)
OBSERVATIONAL (None)
Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
1,600
Enrollment(s)
482
Study location(s)
INTERVENTIONAL (PHASE3)
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
RECRUITING
NCT07582887
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
70
Enrollment(s)
1
Study location(s)
OBSERVATIONAL (None)
Breast Cancer
Metastatic Breast Cancer
Drug-Related Side Effects and Adverse Reactions
Pharmacogenetic Variant
RECRUITING
NCT07582835
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
355
Enrollment(s)
1
Study location(s)
INTERVENTIONAL (PHASE3)
Coronary Artery Disease
Percutaneous Coronary Intervention
Acute Coronary Syndromes
Antiplatelet Therapy
Single Antiplatelet Therapy
Coagulation Factors
COMPLETED
NCT04687761
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
113
Enrollment(s)
15
Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Leukemia, Myeloid, Acute
De Novo
Age More 60yr
16
17
18
19
20